Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERX1000 Phase 1 Safety and PK Study in Obesity
NCT04890873Phase 1Completed
- Sponsor
- ERX Pharmaceuticals
- Start
- Oct 2019
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing ERX1000 with Placebo (2 arms). Primary endpoints: Incidence and severity of adverse events (AEs), Incidence of clinical laboratory abnormalities and 3 more. Started Oct 2019; status: completed.
02
Drugs
ERX1000
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04890873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04890873.